A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

ClinicalTrials.gov ID: NCT00708201

Public ClinicalTrials.gov record NCT00708201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy.

Study identification

NCT ID: NCT00708201
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Enrollment: 280 participants

Conditions and interventions

Conditions

Postoperative Ileus

Interventions

Alvimopan Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2009
Primary completion: Dec 31, 2011
Completion: Dec 31, 2011
Last update posted: Jan 7, 2016

2009 – 2012

United States locations

U.S. sites: 20
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Saddleback Memorial Medical Center	Laguna Hills	California	92653	—
University of Colorado Hospital	Aurora	Colorado	80045	—
University of Miami	Miami	Florida	33136	—
H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida	33612	—
The University of Chicago Medical Center	Chicago	Illinois	60637	—
University of Chicago, Section of Urology MC6038	Chicago	Illinois	60637	—
Indiana University Hospital	Indianapolis	Indiana	46202	—
Ochsner Clinic Foundation	New Orleans	Louisiana	70121	—
University of Michigan Health System	Ann Arbor	Michigan	48109	—
University of Minnesota Hospital	Minneapolis	Minnesota	55455	—
Mayo Clinic	Rochester	Minnesota	55905	—
CRC of Jackson	Jackson	Mississippi	39202	—
University of North Carolina Hospitals	Chapel Hill	North Carolina	27599	—
Wake Forest University Baptist Medical Center	Winston-Salem	North Carolina	27157	—
Cleveland Clinic	Cleveland	Ohio	44195	—
Bend Memorial Clinic	Bend	Oregon	97701	—
Oregon Health and Science University Knight Cancer Institute	Portland	Oregon	97239	—
Vanderbilt University Medical Center, Department of Urology Surgery	Nashville	Tennessee	37232	—
The Methodist Hospital	Houston	Texas	77030	—
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00708201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 7, 2016 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00708201 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →